{
    "clinical_study": {
        "@rank": "73849", 
        "acronym": "LEADERSHIP", 
        "arm_group": [
            {
                "arm_group_label": "AQX-1125", 
                "arm_group_type": "Experimental", 
                "description": "1 x AQX-1125 Capsule daily"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "1 x placebo capsule daily"
            }
        ], 
        "brief_summary": {
            "textblock": "The primary objective of this study is to evaluate the effect of 6 weeks of treatment with\n      once daily administration of AQX-1125 compared to placebo on average daily pain in subjects\n      with interstitial cystitis/bladder pain syndrome (IC/BPS), during and after treatment, using\n      a standardized 11-point numerical rating scale (NRS) pain score recorded by electronic diary"
        }, 
        "brief_title": "Efficacy and Safety of AQX-1125 in IC/BPS", 
        "completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Interstitial Cystitis", 
            "Bladder Pain Syndrome"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Cystitis", 
                "Cystitis, Interstitial", 
                "Somatoform Disorders"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Be females, \u226518 and \u226475 years of age who have consistently had symptoms of bladder\n             pain in addition to urinary urgency and/or urinary frequency for more than 12 months\n\n          -  Have had the diagnosis of interstitial cystitis for > 6 months (but pain for at least\n             12 months) but \u226415 years\n\n          -  Have average daily pain score of at least 5 out of 10 on the 11-point NRS pain scale\n             in the 7 days prior to baseline\n\n          -  Have undergone a cystoscopy and have documented visible signs of bladder bleeding,\n             lesions or glomerulation within the last 36 months prior to baseline.\n\n          -  Subjects if of child bearing potential, must agree to avoid pregnancy and use\n             medically acceptable method of contraception from screening visit and throughout the\n             study.\n\n          -  Must be capable of voiding independently\n\n        Exclusion Criteria:\n\n          -  Pelvic floor pain (>5 out of 10 on the 11-point NRS pain scale following a pelvic\n             pain assessment)\n\n          -  Have a body mass index [BMI] of <18 kg/m2 or >39 kg/m2\n\n          -  Have had a urinary tract infection including bacterial cystitis within the past 30\n             days.\n\n          -  Have greater than 1+ hematuria on dipstick test at screening from an unknown cause\n\n          -  History of previous procedure(s) (augmentation cystoplasty, cystectomy, or\n             cystolysis) that has affected bladder function"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "70", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 18, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01882543", 
            "org_study_id": "AQX-1125-201"
        }, 
        "intervention": {
            "arm_group_label": "AQX-1125", 
            "description": "Synthetic SHIP1 activator", 
            "intervention_name": "AQX-1125", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Interstitial cystitis", 
            "Bladder pain syndrome", 
            "IC/BPS", 
            "AQX-1125", 
            "SHIP1"
        ], 
        "lastchanged_date": "June 2, 2014", 
        "link": {
            "description": "The Interstitial Cystitis Association (ICA) is the only nonprofit association dedicated solely to improving the quality of healthcare and lives of people living with interstitial cystitis (IC).", 
            "url": "http://www.ichelp.org"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Glendora", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "91741"
                    }, 
                    "name": "AQX/CMX site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Desoto", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "75115"
                    }, 
                    "name": "AQX/CMX site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Calgary", 
                        "country": "Canada", 
                        "state": "Alberta", 
                        "zip": "T2V1P9"
                    }, 
                    "name": "AQX/CMX site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kelowna", 
                        "country": "Canada", 
                        "state": "British Columbia"
                    }, 
                    "name": "AQX/CMX site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Victoria", 
                        "country": "Canada", 
                        "state": "British Columbia"
                    }, 
                    "name": "AQX/CMX site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Halifax", 
                        "country": "Canada", 
                        "state": "Nova Scotia", 
                        "zip": "B3H2Y9"
                    }, 
                    "name": "AQX/CMX site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Barrie", 
                        "country": "Canada", 
                        "state": "Ontario"
                    }, 
                    "name": "AQX/CMX site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Brampton", 
                        "country": "Canada", 
                        "state": "Ontario"
                    }, 
                    "name": "AQX/CMX site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Brantford", 
                        "country": "Canada", 
                        "state": "Ontario"
                    }, 
                    "name": "AQX/CMX site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Burlington", 
                        "country": "Canada", 
                        "state": "Ontario"
                    }, 
                    "name": "AQX/CMX site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kingston", 
                        "country": "Canada", 
                        "state": "Ontario"
                    }, 
                    "name": "AQX/CMX site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kitchener", 
                        "country": "Canada", 
                        "state": "Ontario"
                    }, 
                    "name": "AQX/CMX site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Oakville", 
                        "country": "Canada", 
                        "state": "Ontario"
                    }, 
                    "name": "AQX/CMX site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Toronto", 
                        "country": "Canada", 
                        "state": "Ontario"
                    }, 
                    "name": "AQX/CMX Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Toronto", 
                        "country": "Canada", 
                        "state": "Ontario"
                    }, 
                    "name": "AQX/CMX site"
                }, 
                "status": "Suspended"
            }, 
            {
                "contact": {
                    "last_name": "Lesley Carr, MD", 
                    "phone": "416 480 6100", 
                    "phone_ext": "5113"
                }, 
                "facility": {
                    "address": {
                        "city": "Toronto", 
                        "country": "Canada", 
                        "state": "Ontario"
                    }, 
                    "name": "Dr Lesley Carr"
                }, 
                "investigator": {
                    "last_name": "Lesley Carr, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Granby", 
                        "country": "Canada", 
                        "state": "Quebec"
                    }, 
                    "name": "AQX/CMX site"
                }, 
                "status": "Suspended"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Montreal", 
                        "country": "Canada", 
                        "state": "Quebec"
                    }, 
                    "name": "AQX/CMX site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sherbrooke", 
                        "country": "Canada", 
                        "state": "Quebec"
                    }, 
                    "name": "AQX/CMX site"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Canada"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase 2 Study to Evaluate the Efficacy and Safety of AQX-1125 in Subjects With Interstitial Cystitis/Bladder Pain Syndrome Mediated by the Src Homology-2-domain-containing Inositol 5' Phosphatase [SHIP1] Pathway", 
        "other_outcome": {
            "measure": "AQX-1125 concentrations in plasma and urine (trough values)", 
            "safety_issue": "No", 
            "time_frame": "10 weeks"
        }, 
        "overall_contact": {
            "last_name": "Veena Kalia, PhD", 
            "phone": "604 629 9223", 
            "phone_ext": "133"
        }, 
        "overall_official": {
            "affiliation": "Aquinox Pharmaceuticals, Inc.", 
            "last_name": "Stephen B Shrewsbury, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Canada: Health Canada", 
                "United States: Food and Drug Administration"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Difference in the change from baseline in the mean daily bladder pain score based on an 11-point numeric rating scale [NRS] at 2, 4 and 6 weeks recorded by e-diary", 
            "measure": "Change from baseline in the mean daily bladder pain score", 
            "safety_issue": "No", 
            "time_frame": "6 weeks (also at 2 and 4 weeks)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01882543"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Bladder Pain/Interstitial Cystitis Symptom Score [BPIC-SS], interstitial cystitis symptom index/problem index [ICSI/PI] and short form 12 version 2.0 health survey [SF-12v2] questionnaires will be completed at start and end of treatment (and BPIC-SS at 2 and 4 weeks)", 
                "measure": "Difference in the change from baseline in other symptom scores and quality of life measures", 
                "safety_issue": "No", 
                "time_frame": "2, 4 and 6 weeks"
            }, 
            {
                "description": "Adverse events will be collected from signing of informed consent until discharge from study. Other assessments will be completed at regular intervals", 
                "measure": "Safety determined by adverse events [AEs], physical examinations, laboratory tests, electrocardiogram [ECG] and ophthalmic examinations", 
                "safety_issue": "Yes", 
                "time_frame": "10 weeks"
            }
        ], 
        "source": "Aquinox Pharmaceuticals, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Aquinox Pharmaceuticals, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2014"
    }
}